The irritable bowel syndrome treatment market was valued at $1,071 million in 2018, and is estimated to reach at $2,012 million by 2026, registering a CAGR of 8.2% from 2019 to 2026
NEW YORK, March 9, 2020 /PRNewswire/ --
Irritable Bowel Syndrome Treatment Market by Type (IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), and Mixed IBS (IBS-M), Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, and Others), and End User (Hospitals Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2019-2026
Read the full report: https://www.reportlinker.com/p05868976/?utm_source=PRN
The irritable bowel syndrome treatment market was valued at $1,071 million in 2018, and is estimated to reach at $2,012 million by 2026, registering a CAGR of 8.2% from 2019 to 2026.
Irritable bowel syndrome is a gastrointestinal disorder of gut that may be identified by colon muscle contraction. It majorly affects the large intestine. In addition, it is associated with the malfunction of the bowel, and majorly occurs in geriatric population. Diarrhea, constipation, alteration & discomfort in bowel function, bloating, and abdominal pain are some of the common symptoms of irritable bowel syndrome. Endoscopy and blood test are normally performed to detect this irritable bowel syndrome. Irritable bowel syndrome is classified into three types such as IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and mixed IBS. Treatment of irritable bowel syndrome include proper medicines, change in diet, stress relief, and counseling. Medicines used in the treatment of irritable bowel syndrome include rifaximin, eluxadoline, lubiprostone, linaclotide, and others.
Significant increase in prevalence of gastrointestinal diseases and disorders such as alteration of bowel habit, abdominal pain, adoption of sedentary lifestyle, increase in level of stress, and unhealthy diet are the key factors that fuel the growth of the irritable bowel syndrome treatment market. According to the International Foundation for Gastrointestinal Disorders (IFFGD), it was estimated that irritable bowel syndrome affects around 25-45 million in the U.S. in 2016. Moreover, company developing products with symptom specific application and subsequent launches, increase in geriatric population, and rise in awareness programs for irritable bowel syndrome treatment are other factors that contribute toward the growth of the market. Furthermore, rise in prevalence of irritable bowel syndrome in female is expected to further boost the growth of global irritable bowel treatment market during the forecast period. However, high competition among the key players related to pricing and lack of specific treatment which treat all the symptoms of this disorder are expected to hinder the growth of the market.
The irritable bowel syndrome treatment market is segmented into type, product, end user, and region. Depending on type, the market is categorized into IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and Mixed IBS. On the basis of product, the market is classified into rifaximin, eluxadoline, lubiprostone, linaclotide, and others. On the basis of end user, the market is divided into hospitals pharmacies, drug stores & retail pharmacies, and online pharmacies. On the basis of region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
-- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
-- It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
-- A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
-- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Type
-- IBS with Diarrhea (IBS-D)
-- IBS with Constipation (IBS-C)
-- Mixed IBS
By Product
-- Rifaximin
-- Eluxadoline
-- Lubiprostone
-- Linaclotide
-- Others
By End User
-- Hospitals Pharmacies
-- Drug Stores & Retail Pharmacies
-- Online Pharmacies
By Region
-- North America
o U.S.
o Canada
o Mexico
-- Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
-- Asia-Pacific
o Japan
o China
o Australia
o India
o South Korea
o Rest of Asia-Pacific
-- LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
-- Abbott Laboratories
-- Allergan plc
-- Ardelyx Inc.
-- Astellas Pharma Inc.
-- AstraZeneca plc
-- GlaxoSmithKline Plc
-- Johnson & Johnson (McNeil Consumer Healthcare)
-- Novartis AG
-- Sebela Pharmaceuticals Inc.
-- Takeda Pharmaceutical Company Ltd.
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
-- Bausch Health
-- Synthetic Biologics, Inc.
-- Callisto Pharmaceuticals, Inc. (Synergy Pharmaceuticals)
-- Ironwood Pharmaceuticals, Inc.
-- Lexicon Pharmaceuticals, Inc.
Read the full report: https://www.reportlinker.com/p05868976/?utm_source=PRN
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
